Order results by:
| Issue | Title | |
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... of the evaluation of the shadow cost of the budget, it was 313,878.21 Rub for DALY and 365,060.31 Rub for QALY ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... for 1 QALY, and for standard therapy it was 179 552,2 RUB for 1 QALY. Treatment by intraosseous ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... in combination with metformin equal to 1 348368 rub, 1 161874 rub and 537331 rub for QALY in comparison ..." | ||
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... and quality-adjusted life years (QALY). Primary prevention model was focused on patients after myocardial ..." | ||
| Vol 7, No 4 (2014) | IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? | Abstract similar documents |
| V. V. Omelyanovskiy | ||
| "... референтное ценообразование. В рамках внедрения системы референтного ценообразования выделяют внешнее и ..." | ||
| Vol 17, No 3 (2024) | Review of open libraries for pharmacoeconomic analysis in R environment | Abstract similar documents |
| I. A. Lackman, R. I. Sladkov, V. M. Timiryanova | ||
| "... in the R environment was carried out based on the keywords “health economic”, “DALY”, “QALY” in the CRAN ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... was 1.210 mln rub/QALY (by 66.2–88.5% lower than in cases when comparison drugs were used). The budget ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... + alloSCT vs Ch ± RT per life year (LY) and quality-adjusted life year (QALY) was calculated. In the second ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... years, and the model cycle was 1 year. The outcomes used were quality-adjusted life years (QALY), life ..." | ||
| Vol 14, No 4 (2021) | Economic burden of chronic viral hepatitis C | Abstract similar documents |
| R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova | ||
| "... , quality of life adjustment tools (QALY or DALY) were used to estimate the global economic burden. A third ..." | ||
| Vol 6, No 3 (2013) | METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES | Abstract similar documents |
| R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze | ||
| Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| Vol 12, No 2 (2019) | Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available | Abstract similar documents |
| F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev | ||
| "... отдельными ЛП. Разброс темпов прироста/убыли цены референтных ЛП, обращающихся совместно с воспроизведенными ..." | ||
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... государственных закупках референтных ЛП с истекающим сроком патентной защиты воспроизведенными копиями или ..." | ||
| Vol 13, No 2 (2020) | Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union | Abstract similar documents |
| A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
| "... ; сравнение перечня референтных стран, понижающих коэффициентов. Результаты. Выявлены различия в процедурах ..." | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... period of the analysis was 5 years. Quality-adjusted life year (QALY) was used as an efficiency criterion ..." | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... , инкрементальный анализ, анализ «влияния на бюджет». Результаты. Определена стоимость ведения больных шизофренией ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... , инкрементальный анализ, анализ «влияния на бюджет». Результаты. Определена стоимость ведения больных шизофренией ..." | ||
| Vol 7, No 4 (2014) | ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva | ||
| "... регулирования цен на ЖНВЛП к системе всеобщего лекарственного обеспечения населения и референтного ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... +Rd)+(Pom+dex) соответственно. Инкрементальный показатель «затраты–эффективность» (англ. incremental ..." | ||
| Vol 8, No 1 (2015) | SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova | ||
| "... caused with the studied diseases and the number of lost Disability Adjusted Life Years (DALY ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... of life years gained (LYG) and quality-adjusted life years (QALY) were calculated. Results were compared ..." | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | Abstract similar documents |
| A. Yu. Kulikov, I. Yu. Zinchuk | ||
| "... to placebo at 22311 RUB and 21345 RUB, respectively. Cost effectiveness analysis, based on the clinical ..." | ||
| Vol 9, No 2 (2016) | BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak | ||
| "... , the adoption of perampanel is projected to increase drug costs (in millions) by RUB15.2 (1.2%), RUB76.1 (6 ..." | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| "... 198 300 RUB for 6DAC and 1 371 184 RUB for 6FAC. Direct and indirect costs rate of the breast cancer ..." | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
| V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
| "... (QALY) is growing, which makes it advisable to use ART in health care on larger scale. ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS | Abstract similar documents |
| M. V. Protsenko | ||
| "... инкрементальным коэффициентом «затраты – полезность» ниже принятого в России значения порога «готовности платить». ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... , improves the quality of life of patients, adding 0.73 QALY per patient. Modelling suggests ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... gained (LYGs) and 1.12 quality-adjusted life years (QALYs) per 1 patient during lifelong therapy ..." | ||
| Vol 8, No 1 (2015) | PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION | Abstract similar documents |
| M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach | ||
| "... posttransplantation period. Results. Everolimus plus reduced-exposure cyclosporine leads to cost reduction by 161 RUB ..." | ||
| Vol 9, No 4 (2016) | THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE | Abstract similar documents |
| G. E. Ulrikh, A. V. Rudakova | ||
| "... of registration in the case of inclusion in the Essential Drugs List (0,5% R-R amp. 10 ml №10 – 947,74 RUB; 0 ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract similar documents |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| "... considered. Results. Mean direct medical costs of using palbociclib + letrozole were 2 082 333 RUB per ..." | ||
| Vol 14, No 4 (2021) | Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy | Abstract similar documents |
| N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev | ||
| "... rub. (1.13 billion rub. for children and 0.67 billion rub. for adults), compared to regional ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| "... лечения является наименее фармакозатратным в группе приема морфина сульфата (инкрементальный коэффициент ..." | ||
| Vol 14, No 2 (2021) | Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation | Abstract similar documents |
| D. G. Shchurov, V. S. Dombrovskiy | ||
| "... . Критерии клинико-экономической эффективности включали: общие прямые медицинские затраты, инкрементальный ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... добавленных лет жизни с качеством 100% (QALY). Из расчета лечения одного пациента, страдающего ХФ ХМЛ, на ..." | ||
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... на дженерики и используется внутреннее референтное ценообразование. Преобладающим методом определения ..." | ||
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... на дженерики и используется внутреннее референтное ценообразование. Преобладающим методом определения ..." | ||
| Vol 8, No 1 (2015) | BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD | Abstract similar documents |
| A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina | ||
| "... – to 159 153 118 rub, thus the saved means allow to treat with this strategy in addition 29 patients during ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit ..." | ||
| Vol 10, No 2 (2017) | ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) | Abstract similar documents |
| Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina | ||
| "... practice (RUB 4913,67 and 17837,71 respectively). The present analysis demonstrates that the PAP ..." | ||
| Vol 11, No 1 (2018) | CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation | Abstract similar documents |
| A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin | ||
| "... remains cost-effective even if the genotyping costs more than 3893.8 RUB (199% of the current value ..." | ||
| Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
| D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
| "... (QALYs), adverse events, and other clinical outcomes. The search for the relevant information ..." | ||
| Vol 10, No 2 (2017) | CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... стационара. Показаны возможности определения коэффициента инкрементальных затрат схем терапии ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... экономически оправданно у больных с ШЛУ возбудителя с повторными курсами лечения: инкрементальный коэффициент ..." | ||
| 1 - 50 of 57 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
